Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate

Vibalogics will carry out the production at its GMP-accredited facility in Germany where it has recently invested in new equipment to handle larger clinical batches, including a new filling line capable of filling and labeling more than 30,000 vials per batch. Vibalogics is also set to establish a commercial facility in North America for oncolytic viruses, viral vectors for gene therapy approaches and viral vector vaccines in the near future.

“This has been a tremendous challenge for everyone at Vibalogics, but one which the entire team has embraced as an opportunity to use our experience and expertise in the global fight against COVID-19,” said Stefan Beyer, managing director and CEO of Vibalogics. “The business has reacted quickly and efficiently to accommodate this request. With the devotion of our team, and understanding from our customers, we have successfully managed to fulfill this new requirement alongside all of our existing business commitments.”

“This is a fantastic opportunity for the business and our employees to strengthen our position as a global leader in virotherapy manufacturing whilst also providing a key service to our valued customer in its mission to combat the SARS-CoV-2 virus,” added Beyer. “This endeavor is testament to our long-standing and productive partnership with this company, who have shown great trust in our flexible approach, expertise and ability to deliver on time.”

Related Links:
Johnson & Johnson
Janssen Pharmaceutical Companies
Vibalogics GmbH